The continual disruption caused by COVID-19 is starting to have an impact on the drug development programme timings of leading pharma companies;
Sakis Paliouras, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his analysis on the increase in delays in ongoing clinical trials:
“According to GlobalData * 432 clinical trials have been delayed, suspended, or otherwise affected over the last 4 days (to 09.04.20) by the disruption of the COVID-19 pandemic an increase of over 70% on the previous figure of * 253 trial delays.
“The greatest proportion of disrupted clinical trials during this period concerned clinical development in oncology which made up ** 28% of the total trials measured on 8th April followed by the central nervous system and gastrointestinal clinical development areas at ** 14% and ** 8% of the total trials measured respectively.
“As a result leading pharma companies are warning of clinical trial delays for their products, such as Aravive’s Aravive-S6, Immunomedics’ sacituzumab govitecan, and Jazz Pharmaceuticals’ Vyxeos, each with three affected trials. However whether the development of these products will be adversely affected in the long term remains to be seen.
“Country-wide lockdowns as a countermeasure against COVID-19 have severely affected the clinical development of new agents with multiple therapy areas simultaneously affected. The industry may choose to move resources away from other therapy areas and into new, high-priority clinical trials for anti-COVID-19 agents and vaccines.”
* The trial numbers measured was 253 on the 6th of April and 432 – the 9th April 2020
** of the 389 total clinical trials measured on 8th April this is the percentage contribution that each therapy area